Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
Moderna enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Moderna's enterprise value was $94.68B on Nov 11, 2026, against $5.65B a year earlier. Over the last 5 years it ranged from $3.92B to $94.68B, with a median of $32.10B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $94.68B | +1247.5% |
| 2025 | Dec 31, 2025 | $7.03B | -23.1% |
| 2024 | Dec 31, 2024 | $9.14B | -69.8% |
| 2023 | Dec 29, 2023 | $30.32B | -50.4% |
| 2022 | Dec 30, 2022 | $61.16B | -34.9% |
| 2021 | Dec 31, 2021 | $93.96B | +147.1% |
| 2020 | Dec 31, 2020 | $38.03B | +598.4% |
| 2019 | Dec 31, 2019 | $5.45B | +2299.4% |
| 2018 | Dec 31, 2018 | $226.93M | – |
See a number that looks wrong?